Business Wire

Audiencerate: Riccardo Fabbri Joins as Chief Technology Officer — The AI-Driven Phase of the Platforms for SMEs and Media Agencies Begins

21.5.2026 09:00:00 CEST | Business Wire | Press Release

Share

Audiencerate Ltd, one of the few globally certified Google Customer Match Upload Partners and a Microsoft IP Co-sell certified partner with MACC eligibility, today announced the appointment of Riccardo Fabbri as Chief Technology Officer. The appointment marks a phase of dual expansion: the Audiencerate–Postel–Microsoft platform for Italian SMEs, and the Data platform integrated with Google DV360 for Agencies and Data Providers — both evolving toward a model that natively leverages first-party and third-party data through AI and machine learning.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519344995/en/

Riccardo Fabbri, Chief Technology Officer of Audiencerate Ltd. Co-founder and former managing partner of Nohup, recognized by the Financial Times among Europe's leading firms in the sector (2021 and 2022) and acquired by the Havas Group in August 2021. Leads the AI-driven phase of Audiencerate's independent Customer Match infrastructure.

A profile built on twenty years of digital transformation

Fabbri brings to Audiencerate over two decades of experience in software development and cloud architectures. Co-founder in 2004 of Nohup, a digital consultancy in cloud-native development, he led the company to Financial Times recognition among Europe's leading firms in the sector for two consecutive years (2021 and 2022). In August 2021 Nohup was acquired by the Havas Group, bringing its 30 professionals across Milan, Turin, and Udine into Havas CX. The distinctive trait of Fabbri's path is engineering rigor, attention to privacy, and deep knowledge of media operational workflows — an essential asset within the European framework of AI Act, GDPR, and the Italian Consumer Code.

The AI-driven leap for SMEs and Agencies

Under Fabbri's leadership, Audiencerate will accelerate on two parallel tracks. On the SME front, AI and machine learning enable continuous model learning, predictive modeling (propensity scoring, lookalike, CLV) and self-optimization of budget and bid management. On the agency front, advertisers' first-party data serves as seed for lookalike and propensity models enriched with third-party signals: an audience that combines 1P relevance with 3P scale, compliant with privacy and cookie ecosystem evolution.

Statements

"Riccardo's entry is the missing piece," said Gianluca Leotta, President of Audiencerate. "A technologist-entrepreneur who took Nohup to a European exit, lived inside the international media agency world, and knows the technical grammar of our trajectory exactly. It is a long-term choice, consistent with the patrimonial and industrial vision we have always had for this project."

"Audiencerate has built over the years a unique technological asset: a Data Provider position native to both Google and Microsoft ecosystems, with certifications and partnerships that very few companies can claim," said Riccardo Fabbri. "The project is both challenging and exciting. On one side, bringing this infrastructure to millions of Italian SMEs through Postel and Microsoft. On the other, evolving the DV360 offering by drawing on twenty years alongside media agencies: trading desks need models that intelligently fuse first-party and third-party data, while pursuing the automation and scale needed to recover margins the market no longer recognizes as it once did. This is the kind of engineering challenge that resonates with my path as a founder and entrepreneur."

About Audiencerate

Audiencerate Ltd, headquartered in London with offices in Italy and the United States, specializes in data activation, audience intelligence, and AI-driven marketing. Google Customer Match Upload Partner (December 2025), Google Data Provider since 2012, Microsoft IP Co-sell Eligible / MACC Eligible. NEXI is the company's flagship enterprise client in Italy.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260519344995/en/

Contacts

Media contact:
press@audiencerate.com · www.audiencerate.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.audiencerat
e.com&esheet=54538884&newsitemid=20260519344995&lan=en-US&anchor=www.audiencerat
e.com&index=1&md5=2b49e74d6b03c34c97c4b13436db6ae3

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press Release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye